IQVIA Holdings Inc. $IQV Stock Sold by Cibc World Market Inc.

Cibc World Market Inc. trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 30.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 40,763 shares of the medical research company’s stock after selling 17,690 shares during the quarter. Cibc World Market Inc.’s holdings in IQVIA were worth $10,959,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in IQVIA during the second quarter worth approximately $2,811,292,000. Canada Pension Plan Investment Board purchased a new stake in shares of IQVIA during the 2nd quarter valued at $240,911,000. Bank of America Corp DE acquired a new stake in shares of IQVIA during the 2nd quarter worth $235,551,000. Legal & General Group Plc acquired a new stake in shares of IQVIA during the 2nd quarter worth $211,342,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of IQVIA in the 2nd quarter worth $180,296,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $245.68 on Friday. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $284.50. The company has a market capitalization of $40.49 billion, a price-to-earnings ratio of 29.85, a price-to-earnings-growth ratio of 2.35 and a beta of 1.16. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83. The firm’s fifty day moving average price is $267.01 and its 200 day moving average price is $212.56.

IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings data on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The company had revenue of $4.43 billion during the quarter, compared to analysts’ expectations of $4.37 billion. During the same period in the prior year, the company posted $3.00 EPS. The firm’s revenue for the quarter was up 8.0% on a year-over-year basis. On average, research analysts forecast that IQVIA Holdings Inc. will post 11.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Jefferies Financial Group lifted their target price on IQVIA from $220.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. William Blair upgraded IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. Royal Bank Of Canada raised their price objective on IQVIA from $247.00 to $319.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Weiss Ratings lowered IQVIA from a “hold (c+)” rating to a “sell (d+)” rating in a research note on Wednesday, October 28th. Finally, Morgan Stanley boosted their target price on IQVIA from $240.00 to $270.00 and gave the stock an “equal weight” rating in a report on Thursday, September 17th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $294.21.

View Our Latest Research Report on IQVIA

Insider Transactions at IQVIA

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the sale, the insider directly owned 10,890 shares in the company, valued at $2,845,883.70. The trade was a 19.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Sherbet sold 4,446 shares of IQVIA stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $278.83, for a total value of $1,239,678.18. Following the sale, the insider owned 24,989 shares in the company, valued at $6,967,682.87. This represents a 15.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.70% of the company’s stock.

IQVIA Profile

(Free Report)

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.

Further Reading

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.